Achilles Therapeutics plc American Depositary Shares - ACHL STOCK NEWS

Achilles Therapeutics announced promising interim results from the Phase I/II trials evaluating clonal neoantigen-reactive T cells (cNeT) for treating advanced non-small cell lung cancer (NSCLC). Durable partial responses and stable disease were observed in heavily pre-treated patients, suggesting potential for deep clinical responses. The trials demonstrated a favorable safety profile, with no dose-limiting toxicities. Findings will be presented at the ESMO Immuno-Oncology Congress from December 7-9, 2022, and a conference call is scheduled for December 6, 2022.

Achilles Therapeutics has received US patent 11,504,398 for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE). This patent covers various treatment modalities, including vaccines, antibodies, and autologous T cell therapies. The ACE method enhances the identification of patient-specific mutations, using data from the TRACERx study, aiming to improve precision in cancer treatments.

The patented technology employs advanced statistical frameworks to analyze mutations, potentially transforming cancer immunotherapy.

Achilles Therapeutics plc (NASDAQ: ACHL) reported its Q3 2022 financial results, announcing a net loss of $12.5 million, or $0.32 per share, slightly improved from $12.9 million, or $0.34 per share, in Q3 2021. The company has a cash balance of $179.9 million, expected to fund operations through Q2 2025, despite a net decrease of $45.7 million in cash flow due to operating activities and a $40.7 million foreign exchange impact. Updates from ongoing Phase I/IIa trials in NSCLC and melanoma will be presented at the ESMO Immuno-Oncology Congress in December.

Achilles Therapeutics plc (NASDAQ: ACHL) announces a virtual Neoantigen Expert Roundtable on October 13, 2022, at 12:30 PM ET featuring notable panelists, including Co-founder Charles Swanton and Dr. John Haanen. The discussion will focus on the significance of neoantigens in solid tumor therapies, covering neoantigen discovery and tumor-infiltrating lymphocyte (TIL) therapies. Moderated by Neil Canavan of LifeSci Partners, the event will include a live Q&A. Achilles is developing precision T cell therapies targeting clonal neoantigens specific to individual cancer patients.

Achilles Therapeutics plc (NASDAQ: ACHL) reported its Q2 2022 financial results, highlighting a cash balance of $202 million sufficient to fund operations through Q2 2025. The company is advancing its Phase I/IIa clinical trials for cNeT therapies targeting advanced non-small cell lung cancer (NSCLC) and melanoma, with further data expected in Q4 2022. Additionally, regulatory approval for its manufacturing facility enhances production capacity. R&D expenses rose to $14.8 million, while the net loss was $17.3 million or $0.44 per share, reflecting increased clinical activity.

Achilles Therapeutics (NASDAQ: ACHL) leads a consortium awarded a €4 million ($4.2 million) grant from Horizon Europe to develop a first-in-class smart bioprocessing manufacturing platform for personalized cell therapies. This initiative aims to enhance manufacturing processes by incorporating advanced sensors and machine-learning controls. Of the total funding, approximately €1.4 million ($1.5 million) will go to Achilles. The project, named SMARTER, involves collaboration with leading institutions to advance cancer immunotherapy.

Achilles Therapeutics (NASDAQ: ACHL) announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board, effective July 1, 2022. Taylor has over 25 years of experience in pharmaceutical and biotech deal-making, previously at Sosei Heptares and GSK. His focus will be on enhancing strategic partnerships for precision T cell therapies targeting solid tumors. Dr. Yee is a respected leader in immuno-oncology, contributing to the advancement of adoptive cellular therapy at MD Anderson Cancer Center.

Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has won the PING Innovation Award for its advancements in precision T cell therapies targeting clonal neoantigens. This award recognizes organizations making a significant impact in pharmaceuticals and life sciences. CEO Iraj Ali highlighted the company's commitment to developing individualized cancer treatments using AI-powered bioinformatics and unique patient data. Achilles is currently conducting two Phase I/IIa trials for advanced non-small cell lung cancer and melanoma, showcasing its innovative approach to cancer treatment.

Achilles Therapeutics (ACHL) announced key developments in its clinical trials and business operations as of May 10, 2022. They dosed the first patient in the CHIRON trial for advanced non-small cell lung cancer (NSCLC) with a higher-dose cNeT therapy and initiated enrollment for THETIS Cohort B, targeting metastatic melanoma. The company reported a robust cash balance of $236.9 million, sufficient to maintain operations into the second half of 2024. R&D expenses rose to $13 million, reflecting increased trial activities, while the net loss for Q1 2022 stood at $17.4 million.